MarginsXMarginsX
Home › Markets › Health Care › HCM

HUTCHMED (China) Limited (HCM)

HCM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.73
-1.14% on the day
Market cap
$2.6B
Mid cap
Revenue · 2025
$548.5M
-13.0% on 2024
Net income · 2025
$456.9M
83.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1648257/000110465926023822/0001104659-26-023822-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHCM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryHong Kong
IPO year2016
SEC CIK0001648257

Financials · 2025

LineValue
Revenue$548.5M
Net income$456.9M
Operating income-$39.2M
Net margin83.3%
Operating margin-7.1%
Revenue growth-13.0%
Cash$71.3M
Total assets$1.8B
P/E (computed)5.6×
P/S (computed)4.7×

Warning signs

Cash runway
13.2 months
$71.3M cash at December 31, 2025
Share count, 1 year
+0.1%
2024-12-31 to 2025-12-31 · +0.9% over 3 years
Going-concern doubt
No
20-F filed March 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Group ' s ability to continue as a going concern for a reasonable period of time."
20-F 2026-03-05
Cash and burn$71.3M cash; operating cash flow -$16.2M a quarter.Report 2025-12-31
Shares outstanding174,465,524 (2025-12-31); 174,320,219 a year earlier; 172,955,068 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers Zhong Tian LLP, Shenzhen, ChinaPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$548.5M$456.9M-$64.7M$71.3M$118.1M$548.5M20-F 2026-03-05
FY 2024
2024-12-31
$630.2M$37.7M$497K$154.0M$106.2M$630.2M20-F 2026-03-05
FY 2023
2023-12-31
$838.0M$100.8M$219.3M$283.6M$110.5M$838.0M20-F 2026-03-05
FY 2022
2022-12-31
$426.4M-$360.8M-$268.6M$313.3M$18.1M$426.4M20-F 2023-02-28
FY 2021
2021-12-31
$356.1M-$194.6M-$204.2M$377.5M$26.9M$356.1M20-F 2023-02-28
FY 2020
2020-12-31
$228.0M-$125.7M-$62.1M$235.6M$26.9M$228.0M20-F 2023-02-28
FY 2019
2019-12-31
$204.9M-$106.0M-$80.9M$121.2M$26.8M$204.9M20-F 2022-03-03
FY 2018
2018-12-31
$214.1M-$74.8M-$32.8M$86.0M$26.7M$214.1M20-F 2021-03-04

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-1.7%
1 month+10.4%
3 months+22.5%
Year to date+11.8%
1 year-1.8%
From 52-week high-7.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MBXMBX Biosciences Inc.$53.12-5.04%$2.6B
ZLABZai Lab Limited$23.47-4.59%$2.6B
XNCRXencor Inc.$35.40-4.56%$2.7B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
VCREVicore Pharma Holding AB$10.16-1.93%$2.9B
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier